Table 2:
ADC payloads tested in the high throughput screen
| Compound | Vendor | Mechanism of action |
|---|---|---|
| N-Acetyl-Calicheamicin gamma1 | Levena Biopharma | DNA damage |
| DM1 | Levena Biopharma | Microtubule disruptor |
| PBD Dimer (SGD-1882) | Levena Biopharma | DNA damage |
| Monomethyl Auristatin E (MMAE) | Levena Biopharma | Microtubule disruptor |
| SN-38 | ChemieTek | Topoisomerase inhibition |
| DM4 | Levena Biopharma | Microtubule disruptor |
| alpha-Amanitin | Levena Biopharma | RNA polymerase inhibitor |
| Duocarmycin DM | Levena Biopharma | DNA alkylation |
| Monomethyl Auristatin F (MMAF) | Levena Biopharma | Microtubule disruptor |
| PNU 159682 | Levena Biopharma | Topoisomerase inhibition |
| Maytansinol | Levena Biopharma | Microtubule disruptor |
| Duocarmycin SA | Levena Biopharma | DNA alkylation |
| Monomethyl Dolastatin 10 | Levena Biopharma | Microtubule disruptor |
| Vinblastine Sulfate | Microsource Discovery | Microtubule disruptor |
| Ansamitocin P3 | Levena Biopharma | Microtubule disruptor |
| Calicheamicin gamma1 | Levena Biopharma | DNA damage |
| Nemorubicin | Levena Biopharma | Topoisomerase inhibition |
| Doxorubicin | Selleck Chem | Topoisomerase inhibition |
| Tubulysin IM-2 | Levena Biopharma | Microtubule disruptor |
| Auristatin F | Levena Biopharma | Microtubule disruptor |
| Camptothecin | Selleck Chem | Topoisomerase inhibition |
| Dasatinib | Selleck Chem | Tyrosine kinase inhibitor |
| Duocarmycin MA | Levena Biopharma | DNA alkylation |
| Duocarmycin TA | Levena Biopharma | DNA alkylation |
| Tubulysin M | Levena Biopharma | Microtubule disruptor |
| Auristatin E | Levena Biopharma | Microtubule disruptor |
| Dolastatin 10 | Levena Biopharma | Microtubule disruptor |